 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Anthony Elias and Christina Finlayson.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.551 |
|
|
|
-
Weitzel LR, Byers T, Allen J, Finlayson C, Helmke SM, Hokanson JE, Hunsucker SW, Murphy JR, Newell K, Queensland KM, Singh M, Wischmeyer PE, Duncan MW, Elias A. Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. Breast Cancer Res Treat. 2010 Nov; 124(2):297-305.
Score: 0.089
-
Brooks G, Borges V, Singh M, Rabinovitch R, Finlayson C, Elias A. A perimenopausal woman with a small, ER/HER2-positive, node-negative breast cancer. Oncology (Williston Park). 2008 Oct; 22(11):1270-6.
Score: 0.082
-
Bowles DW, Rabinovitch R, Borges V, Urquhart A, Singh M, Finlayson C, Elias A. A young woman with a small ER-positive breast cancer, a micrometastatic axillary lymph node, and an intermediate oncotype DX recurrence score. Oncology (Williston Park). 2007 Sep; 21(10):1212-7.
Score: 0.076
-
Menter A, Urquhart A, Borges V, Rabinovitch R, Singh M, Robinson W, Seligman P, Finlayson C, Elias A. A woman with primary breast cancer and a solitary sternal metastasis. Oncology (Williston Park). 2006 Aug; 20(9):1068-71, 1075, 1079-80.
Score: 0.070
-
Urquhart A, Borges V, Rabinovitch R, Singh M, Robinson W, Seligman P, Arya J, Finlayson C, Elias A. A postmenopausal woman with early-stage breast cancer and borderline hormone-receptor staining. Oncology (Williston Park). 2005 Mar; 19(3):278, 283-4, 287 passim.
Score: 0.064
-
Overholser L, Shagisultanova E, Rabinovitch RA, Kounalakis N, Diamond J, Finlayson CA, Fisher CM, Kabos P, Elias AD, Borges VF, Mayordomo J. Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies. Oncology (Williston Park). 2016 12 15; 30(12):1063-70.
Score: 0.036
-
Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat. 2012 Sep; 135(2):415-32.
Score: 0.027
-
Kounalakis N, Diamond J, Rusthoven K, Horn W, Jindal S, Wisell J, Klein CE, Elias A, Finlayson C, Borges VF. Diagnosis of invasive lobular carcinoma in a young woman presenting with pleomorphic lobular carcinoma in situ on core biopsy. Oncology (Williston Park). 2011 Apr 15; 25(4):351-6.
Score: 0.024
-
Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat. 2011 Jul; 128(1):45-55.
Score: 0.023
-
Diamond JR, Finlayson CA, Thienelt C, Kabos P, Hardesty L, Barbour L, Klein CE, Rabinovitch R, Elias A, Borges VF. Early-stage BRCA2-linked breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state. Oncology (Williston Park). 2009 Aug; 23(9):784-91.
Score: 0.022
-
Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VF, Elias AD, Horwitz KB. Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Res Treat. 2008 Dec; 112(3):489-501.
Score: 0.020
-
Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Trapp S, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008 Dec; 112(3):475-88.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|